TD-139 is a potent and selective inhibitor of galectin-3, a protein involved in inflammation, fibrosis, and cancer progression. It has shown promise in preclinical and clinical studies for treating chronic fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). By blocking galectin-3 activity, TD-139 reduces lung inflammation and fibrosis, helping to preserve lung function. It is administered via inhalation, allowing direct delivery to the lungs, which enhances efficacy and minimizes systemic side effects. Research also explores its potential in other galectin-3-mediated conditions, including liver fibrosis, cardiovascular diseases, and certain cancers, making it a versatile therapeutic candidate in chronic inflammatory and fibrotic disorders.